AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8697854 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous dilational tracheostomy (PDT)
Number of subjects: 53
Study 8697854 — intervention group
Group type: COMPARATOR
Intervention: Surgical tracheostomy (ST)
Number of subjects: 53
Study 1726209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil suspension (3 and 6 mg/kg)
Number of subjects: 476
Study 6753114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 0
Study 6753114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (75 mg daily)
Number of subjects: 0
Study 6753114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31876200 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + CsA (7.5 mg MTX and 2.5 mg/kg CsA)
Number of subjects: 40
Study 31876200 — intervention group
Group type: COMPARATOR
Intervention: MTX + Placebo (7.5 mg MTX and placebo)
Number of subjects: 40
Study 31876200 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + CsA
Number of subjects: 40
Study 31876200 — intervention group
Group type: COMPARATOR
Intervention: MTX + Placebo
Number of subjects: 40
Study 31778618 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemochromatosis cases
Number of subjects: 37092
Study 29872859 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SpO2 target range (85%-89%)
Number of subjects: 4965
Study 29872859 — intervention group
Group type: COMPARATOR
Intervention: Higher SpO2 target range (91%-95%)
Number of subjects: 4965
Study 25782170 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ambroxol (AXS)
Number of subjects: 511
Study 25782170 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ambroxol (AXS)
Number of subjects: 511
Study 25782170 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg ambroxol (AXS)
Number of subjects: 511
Study 25782170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study 24056366 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothguide Trainer (TT) and Toothguide Training Box (TTB) training
Number of subjects: 78
Study 24056366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 78
Study 21324570 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 4x500 mg orally within 24 hours
Number of subjects: 18
Study 21324570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19470041 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid photodynamic therapy (ALA-PDT)
Number of subjects: 30
Study 19470041 — intervention group
Group type: COMPARATOR
Intervention: 5% imiquimod cream (IMIQ)
Number of subjects: 30
Study 17481859 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) at a dosage of 0.1 mg/kg
Number of subjects: 3
Study 15047131 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg rhIGF‐I/IGFBP‐3 for one‐week intervals
Number of subjects: 10
Study 15047131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15047131 — intervention group
Group type: COMPARATOR
Intervention: Normal children (comparison group)
Number of subjects: 10
Study 11673081 — intervention group
Group type: COMPARATOR
Intervention: Centenarian males
Number of subjects: 54
Study 11673081 — intervention group
Group type: COMPARATOR
Intervention: Younger control men
Number of subjects: 54
Study 11673081 — intervention group
Group type: COMPARATOR
Intervention: Centenarian females
Number of subjects: 54
Study 11673081 — intervention group
Group type: COMPARATOR
Intervention: Young women
Number of subjects: 54
Study 11673081 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 54
Study 9551246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (100 mg/kg on the first day followed by 75 mg/kg/day)
Number of subjects: 82
Study 9551246 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (200 mg/kg/day in four divided doses)
Number of subjects: 82
Study 9551246 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 82
Study 7624192 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous condition
Number of subjects: 10
Study 7624192 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogeneous condition
Number of subjects: 10
Study 7624192 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 10
Study 2677126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 100
Study 2677126 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 100
Study 233545 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metaproterenol administered daily for 3 months
Number of subjects: 0
Study 233545 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 0
Study 31303295 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility birth
Number of subjects: 119244
Study 31303295 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility birth in areas closer to CEmOC facilities
Number of subjects: 119244
Study 31303295 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing wealth
Number of subjects: 119244
Study 31303295 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing distance from childbirth facilities
Number of subjects: 119244
Study 25851102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 3232
Study 25851102 — intervention group
Group type: COMPARATOR
Intervention: Metformin or placebo
Number of subjects: 3232
Study 25851102 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 3232
Study 24034963 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer oriented behavioral intervention including six small group peer educator-training sessions and three booster sessions plus HIV testing and counseling (HTC)
Number of subjects: 419
Study 24034963 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer oriented behavioral intervention
Number of subjects: 419
Study 24034963 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only HIV testing and counseling (HTC)
Number of subjects: 419
Study 21991942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator lung function
Number of subjects: 5887
Study 21991942 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-bronchodilator lung function
Number of subjects: 5887
Study 21991942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator lung function (Stage 3 or 4 disease)
Number of subjects: 5887
Study 21991942 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-bronchodilator lung function (Stage 3 or 4 disease)
Number of subjects: 5887
Study 21991942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator lung function (Year 5 sample)
Number of subjects: 5887
Study 21991942 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-bronchodilator lung function (Year 5 sample)
Number of subjects: 5887
Study 18975305 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 356
Study 18975305 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 356
Study 18975305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 18975305 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 356
Study 16867142 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effects analysis using fecal terminal restriction fragment length polymorphism data sets
Number of subjects: 0
Study 16867142 — intervention group
Group type: EXPERIMENTAL
Intervention: Principle components analysis and cluster analysis
Number of subjects: 0
Study 16867142 — intervention group
Group type: EXPERIMENTAL
Intervention: Large within-subject sample size and multiple baseline samples
Number of subjects: 0
Study 12622345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular phone monitoring (CM)
Number of subjects: 20
Study 12622345 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil self-monitoring (PM)
Number of subjects: 20
Study 10683797 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon5
Number of subjects: 35
Study 10683797 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoat
Number of subjects: 35
Study 10683797 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon5 and Viscoat
Number of subjects: 35
Study 8821083 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hippocampal sclerosis
Number of subjects: 0
Study 8821083 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with frontal lobe lesions
Number of subjects: 0
Study 8821083 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 9511639 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgaphase
Number of subjects: 82
Study 9511639 — intervention group
Group type: COMPARATOR
Intervention: Dispersalloy
Number of subjects: 82
Study 9511639 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalga 43
Number of subjects: 82
Study 9511639 — intervention group
Group type: EXPERIMENTAL
Intervention: Permite C
Number of subjects: 82
Study 6468034 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 1500 mg Cefuroxim (Zinazef) for three days, starting 1 h prior to the operation
Number of subjects: 61
Study 6468034 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 61
Study 30452914 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging (AFI)
Number of subjects: 802
Study 30452914 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 802
Study 30265153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide for 1 year followed by placebo for 1 year
Number of subjects: 142
Study 30265153 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil for 2 years
Number of subjects: 142
Study 30265153 — intervention group
Group type: COMPARATOR
Intervention: Pooled groups (Cyclophosphamide and Mycophenolate)
Number of subjects: 142
Study 27216329 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training (PEP-PA) for children with severe ADHD
Number of subjects: 0
Study 27216329 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher training (PEP-TE) for children with severe ADHD
Number of subjects: 0
Study 27216329 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training (PEP-PA) for children with no or mild ADHD
Number of subjects: 0
Study 27216329 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher training (PEP-TE) for children with no or mild ADHD
Number of subjects: 0
Study 24003241 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaifenesin (GGE) 600 mg extended-release tablets, taken twice daily for 8 days
Number of subjects: 378
Study 24003241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 22138342 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET-assisted management
Number of subjects: 430
Study 22138342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to FDG PET recommendations
Number of subjects: 430
Study 22138342 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 430
Study 19930235 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Naltrexone + Brief Behavioral Compliance Enhancement Therapy (BBCET) + treatment as usual (TAU)
Number of subjects: 0
Study 19930235 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Counseling Intervention (BCI) + TAU
Number of subjects: 0
Study 19930235 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone + BBCET + BCI + TAU
Number of subjects: 0
Study 19930235 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 0
Study 17984668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 2334
Study 17984668 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 2334
Study 17984668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 2334
Study 16020621 — intervention group
Group type: EXPERIMENTAL
Intervention: Community involvement in data collection roles
Number of subjects: 0
Study 12390317 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease Inhibitor (PI)
Number of subjects: 0
Study 12390317 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Number of subjects: 0
Study 12390317 — intervention group
Group type: COMPARATOR
Intervention: Comparison between NNRTI and PI cohorts
Number of subjects: 0
Study 12390317 — intervention group
Group type: COMPARATOR
Intervention: CCR5 expression
Number of subjects: 0
Study 12390317 — intervention group
Group type: COMPARATOR
Intervention: CCR5 Delta32 genotyping
Number of subjects: 0
Study 9813869 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (40 min of supervised exercise every other day at 70% of heart rate reserve for 10 days)
Number of subjects: 50
Study 9813869 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control (NEX)
Number of subjects: 50
Study 8749873 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole alone (group 1, controls, n = 6)
Number of subjects: 16
Study 8749873 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole and diltiazem (group 2, n = 5)
Number of subjects: 16
Study 8749873 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole and diltiazem (group 3, n = 5)
Number of subjects: 16
Study 8749873 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (10 mg) intravenous administration
Number of subjects: 16
Study 1977380 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 1977380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38969 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 38969 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 38969 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0
Study 38969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31488485 — intervention group
Group type: COMPARATOR
Intervention: EPA schools (n=154)
Number of subjects: 1607
Study 31488485 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-EPA schools (n=788)
Number of subjects: 1607
Study 31488485 — intervention group
Group type: COMPARATOR
Intervention: EPA schools (primary teachers)
Number of subjects: 1607
Study 31488485 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-EPA schools (primary teachers)
Number of subjects: 1607
Study 28973363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver and PEEP titration according to best respiratory-system compliance (n=501)
Number of subjects: 1010
Study 28973363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver and PEEP titration (n=501)
Number of subjects: 1010
Study 28973363 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP (n=509)
Number of subjects: 1010
Study 26529014 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA at acupoint-sites (2.5 U each site, 25 U per subject)
Number of subjects: 102
Study 26529014 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA at fixed-sites (2.5 U each site, 25 U per subject)
Number of subjects: 102
Study 26529014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 23912836 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-877ER
Number of subjects: 20
Study 23912836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21876879 — intervention group
Group type: EXPERIMENTAL
Intervention: Semipermeable membrane
Number of subjects: 42
Study 21876879 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study 19969213 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with superior hinge position
Number of subjects: 190
Study 19969213 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with temporal hinge position
Number of subjects: 190
Study 19969213 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with 45-degree hinge angle
Number of subjects: 190
Study 19969213 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with 90-degree hinge angle
Number of subjects: 190
Study 19969213 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with 100 microm flap thickness
Number of subjects: 190
Study 19969213 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with 130 microm flap thickness
Number of subjects: 190
Study 19969213 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK (all groups)
Number of subjects: 190
Study 16453956 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate removal via rigid endoscopy
Number of subjects: 60
Study 16453956 — intervention group
Group type: COMPARATOR
Intervention: Observation for 16 hours with repeat x-ray
Number of subjects: 60
Study 16453956 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 60
Study 14978636 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary changes, use of laxatives, cognitive and behavioral interventions (toilet training)
Number of subjects: 0
Study 14978636 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiarrheal agents
Number of subjects: 0
Study 14978636 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectal biofeedback
Number of subjects: 0
Study 14978636 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged use of enemas
Number of subjects: 0
Study 14978636 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for congenital anorectal anomalies
Number of subjects: 0
Study 14978636 — intervention group
Group type: EXPERIMENTAL
Intervention: Continent appendicostomy (Malone procedure)
Number of subjects: 0
Study 14978636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cecostomy
Number of subjects: 0
Study 11759935 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery intima-media thickness greater than 0.8 mm
Number of subjects: 266
Study 11759935 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive group with coronary artery disease
Number of subjects: 266
Study 11759935 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with concomitant hypertension
Number of subjects: 266
Study 11759935 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery intima-media thickness
Number of subjects: 266
Study 9387948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal eupnoeic inhalation of cold dry air (‐5 degrees C)
Number of subjects: 40
Study 8110915 — intervention group
Group type: EXPERIMENTAL
Intervention: CMI challenge followed 2 weeks later by CMI rechallenge
Number of subjects: 0
Study 8110915 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge followed 2 weeks later by CMI challenge
Number of subjects: 0
Study 8110915 — intervention group
Group type: EXPERIMENTAL
Intervention: CMI challenge followed 4 weeks later by CMI rechallenge
Number of subjects: 0
Study 3099442 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 28
Study 3099442 — intervention group
Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 28
Study 3099442 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 28
Study 30559807 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy for three months
Number of subjects: 67
Study 30559807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diet therapy)
Number of subjects: 67
Study 25712086 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 - one long instrument, one standard length instrument and standard length laparoscope
Number of subjects: 23
Study 25712086 — intervention group
Group type: COMPARATOR
Intervention: Control - standard length instruments and standard length laparoscope
Number of subjects: 23
Study 23592701 — intervention group
Group type: EXPERIMENTAL
Intervention: Early thoracic radiotherapy (TRT) administered concurrently with the first cycle of chemotherapy
Number of subjects: 222
Study 23592701 — intervention group
Group type: COMPARATOR
Intervention: Late thoracic radiotherapy (TRT) administered concurrently with the third cycle of chemotherapy
Number of subjects: 222
Study 23592701 — intervention group
Group type: EXPERIMENTAL
Intervention: Early TRT
Number of subjects: 222
Study 23592701 — intervention group
Group type: COMPARATOR
Intervention: Late TRT
Number of subjects: 222
Study 20118149 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 4299
Study 20118149 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple aspiration thrombectomy
Number of subjects: 4299
Study 18502484 — intervention group
Group type: COMPARATOR
Intervention: Standard Snodgrass urethroplasty
Number of subjects: 40
Study 18502484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathieu‐Incised Plate (Mathieu‐IP) technique
Number of subjects: 40
Study 15900994 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater academic incentive reward structure
Number of subjects: 210
Study 15900994 — intervention group
Group type: COMPARATOR
Intervention: Standard academic reward structure (control group)
Number of subjects: 210
Study 12559643 — intervention group
Group type: EXPERIMENTAL
Intervention: Five courses of therapy
Number of subjects: 1078
Study 12559643 — intervention group
Group type: COMPARATOR
Intervention: Four courses of therapy
Number of subjects: 1078
Study 12559643 — intervention group
Group type: EXPERIMENTAL
Intervention: Five courses of therapy (early results)
Number of subjects: 1078
Study 12559643 — intervention group
Group type: COMPARATOR
Intervention: Four courses of therapy (early results)
Number of subjects: 1078
Study 10698464 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthium
Number of subjects: 12
Study 10698464 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur
Number of subjects: 12
Study 10698464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 12
Study 7847530 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant contraceptive implants (immediate insertion within 48 hours of delivery)
Number of subjects: 250
Study 7847530 — intervention group
Group type: COMPARATOR
Intervention: Control group (Norplant insertion at 4- to 6-week postpartum visit)
Number of subjects: 250
Study 1942508 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg.kg‐1 + 10 ml saline
Number of subjects: 21